Skip to main content
FDA Approved 0 views

L-Carnitine

L-Carnitine (levocarnitine) is a naturally occurring amino acid derivative essential for transporting long-chain fatty acids into mitochondria for energy production via beta-oxidation.

L-Carnitine molecular structure

Overview

L-Carnitine (levocarnitine) is a naturally occurring amino acid derivative essential for transporting long-chain fatty acids into mitochondria for energy production via beta-oxidation. Synthesized endogenously from lysine and methionine, it plays critical roles in energy metabolism, particularly in high-energy tissues like heart, brain, and skeletal muscle. FDA approved as Carnitor® for treating primary and secondary carnitine deficiency. Various forms exist including Acetyl-L-Carnitine (ALCAR) for cognitive support, L-Carnitine L-Tartrate (LCLT) for exercise recovery, and Propionyl-L-Carnitine for cardiovascular health. Extensively studied with over 200 clinical trials examining effects on weight management, exercise performance, heart health, cognitive function, and male fertility.

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

LevocarnitineL-3-hydroxy-4-N,N,N-trimethylaminobutyrateVitamin BTCarnitor (brand name)L-carnitine (INN: levocarnitine)

Status: FDA approved as Carnitor® for primary and secondary carnitine deficiency; widely used supplement

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Fatty acid metabolism and mitochondrial functionWeight loss and body compositionFatiguePrimary and secondary carnitine deficiencyType 2 diabetes

Available Evidence

Human

A systematic review and meta-analysis of 37 randomized controlled trials with dose-response analysis found that L-carnitine supplementation reduced body weight and improved body composition, with clearer effects at roughly 2 g/day or more. Levocarnitine (Carnitor) is FDA-approved for primary and secondary carnitine deficiency; effects in the general population are modest and heterogeneous.

Animal

Rodent studies confirm that carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation and that supplementation increases fatty acid oxidation in muscle and liver.

In Vitro

Mechanistic studies establish carnitine as an essential cofactor in the CPT-I/CPT-II system that transports long-chain fatty acyl groups across the inner mitochondrial membrane.

Uncertain

Claims of meaningful fat loss or performance enhancement in healthy, well-nourished individuals remain debated; trial effects are small, and some analyses show significant heterogeneity.

Key Studies & Findings

2 studies

Benefits & Effects

4 documented

Maximum bioavailability (100% vs 14-18% oral)

clinical

rapid onset of action

clinical

bypasses gut microbiome conversion to TMAO

clinical

particularly useful for carnitine deficiency states and clinical settings

clinical

No side effects data available yet.

This peptide may have limited safety data.

Limitations & Open Questions

Weight-loss effects in trials are modest and heterogeneous; most trials are short-term; evidence for athletic performance, cognitive, and fatigue claims is mixed; supplementation is not a substitute for treating documented deficiency.

Pharmacology

L-carnitine is a quaternary ammonium compound synthesized from lysine and methionine that transports long-chain fatty acids across the mitochondrial membrane for beta-oxidation. Oral bioavailability of high doses is limited (roughly 14-18%), plasma levels peak within hours of dosing, and large stores are maintained in skeletal muscle; trial doses typically range from about 1 to 4 g/day, with dose-response analyses favoring at least 2 g/day for weight-related outcomes.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

50 mg/kg/day

Route: Injectable
Half-life: 17 hrs

Research Protocols

Carnitine deficiency

Dose
50 mg/kg/day
Frequency
Divided doses or continuous
Route
IV

Hemodialysis support

Dose
10-20 mg/kg
Frequency
Post-dialysis
Route
IV - Slow push

Fat metabolism / Performance

Dose
500-1500mg
Frequency
1-3x weekly
Route
SubQ or IM

Critical illness

Dose
Up to 300 mg/kg/day
Frequency
Divided or continuous
Route
IV - Infusion

Research protocols are for educational purposes only. Always consult qualified medical professionals.

Frequently Asked Questions

Is L-carnitine an approved drug?

Yes, as levocarnitine (Carnitor) it is FDA-approved for primary and secondary carnitine deficiency, but it is not approved for weight loss in the general population.

Does L-carnitine reliably cause weight loss?

Meta-analytic evidence shows a statistically significant but modest effect on weight and body composition, mainly in trials using about 2 g/day or more; individual results vary.

Research Citations

1

Weight Loss Meta-Analysis (2020)

(2020)

2

Cardiovascular Secondary Prevention (2013)

(2013)

3

Exercise Recovery LCLT Study (2021)

(2021)

Related Resources

Quick Facts

Mechanism

Injectable L-Carnitine delivers the compound directly to circulation, bypassing the limitations of intestinal absorption. This provides immediate availability for fatty acid transport into mitochondria. IV/IM routes are preferred in clinical settings for carnitine deficiency and dialysis patients.

Safety Information

FDA-approved for specific indications - well-established safety profile. May cause injection site discomfort or temporary warmth. High doses can cause fishy body odor due to TMA production. Use caution in hypothyroidism - may inhibit thyroid hormone action. Monitor if on anticoagulants (warfarin) - may enhance effect. Renal patients should be monitored for TMA/TMAO accumulation.

View All Peptides